About Neupogen (filgrastim) Dosing

This information supports the use of the Neupogen (filgrastim) Dosing Calculator. Filgrastim is a granulocyte colony-stimulating factor (G-CSF) used to stimulate the production of neutrophils (a type of white blood cell) in the bone marrow. Accurate, weight-based dosing is critical for achieving therapeutic goals while minimizing potential side effects. The following sections provide context for the calculator's inputs and outputs.

Outputs Explained

After entering the required patient data, the calculator provides two primary results:

• Total Calculated Daily Dose (mcg): The total amount of filgrastim, in micrograms, to be administered per day based on the patient's weight and the standard dosing rate for the selected indication. This value is typically rounded to the nearest whole number.
• Volume to Administer (mL): The volume of the drug solution to be drawn up for administration. This is calculated by dividing the total daily dose by the selected drug concentration (e.g., 300 mcg/mL or 600 mcg/mL).

How to Use the Calculator

To ensure an accurate calculation, follow these steps:

1. Select Clinical Indication: Choose the appropriate reason for treatment from the dropdown menu. Each indication corresponds to a specific, pre-programmed dosing rate (mcg/kg/day).
2. Enter Patient Weight: Input the patient's current body weight. Ensure the correct unit (kg or lbs) is selected, as the tool will automatically convert lbs to kg for the calculation.
3. Select Drug Concentration: Choose the concentration of the filgrastim formulation being used. Vials are typically 300 mcg/mL, while prefilled syringes often contain a 600 mcg/mL solution.

Dosing Overview by Indication

The calculator uses standard dosing recommendations from the Neupogen® prescribing information. Common starting doses are:

• Chemotherapy-Induced Neutropenia: 5 mcg/kg/day.
• Mobilization of Progenitor Cells (PBSC): 10 mcg/kg/day.
• AML following Induction/Consolidation: 5 mcg/kg/day.
• Severe Chronic Neutropenia (SCN): Starting doses are individualized. The calculator uses 5 mcg/kg/day as a reference for idiopathic/cyclic SCN. Congenital SCN often starts at 6 mcg/kg twice daily.
• Acute Radiation Exposure (H-ARS): 10 mcg/kg/day.

Switching Filgrastim Products

Switching between brand-name Neupogen and its biosimilars (e.g., Zarxio®, Nivestym®) should only be done under the guidance of a qualified healthcare professional. While biosimilars have been shown to have no clinically meaningful differences from the reference product, specific institutional policies and prescriber judgment should guide any transitions. This calculator is intended for filgrastim products and should not be used for other G-CSF medications like pegfilgrastim (Neulasta®).

Handling a Missed Dose

If a dose of filgrastim is missed, the patient or caregiver should contact their healthcare provider for instructions. Generally, the missed dose should be administered as soon as it is remembered. However, if it is almost time for the next scheduled dose, the provider may advise skipping the missed dose and resuming the regular dosing schedule. Patients should not administer a double dose to make up for a missed one.

Safety Alerts

Filgrastim is associated with several important safety considerations. Always consult the full Prescribing Information before administration. Key warnings include:

Frequently Asked Questions

Why are there different doses for each indication?

The required level of neutrophil stimulation varies. For example, mobilizing stem cells for transplant (PBSC) requires a more potent stimulus (10 mcg/kg) than managing neutropenia after standard chemotherapy (5 mcg/kg).

How does the calculator handle weight conversion?

If you enter weight in pounds (lbs), the calculator automatically converts it to kilograms (kg) using the standard conversion factor (1 kg ≈ 2.20462 lbs) before calculating the dose.

Can this tool be used for pegfilgrastim (Neulasta®)?

No. This calculator is specifically for filgrastim (Neupogen® and its biosimilars), which is typically dosed daily. Pegfilgrastim is a long-acting formulation with a different dosing schedule (e.g., once per chemotherapy cycle) and should not be calculated using this tool.

What starting dose does the calculator use for Severe Chronic Neutropenia (SCN)?

The calculator uses a starting dose of 5 mcg/kg/day, which is common for idiopathic or cyclic neutropenia. Dosing for SCN is highly individualized based on ANC response and the specific subtype (e.g., congenital neutropenia often requires higher or more frequent dosing).

Does the final volume need to be rounded?

The calculator provides a precise volume. Clinical practice often involves rounding to a practical, measurable volume (e.g., to the nearest 0.01 mL). Additionally, the total dose may be rounded to the nearest vial or prefilled syringe size to minimize waste, per institutional protocol.

Why is it important to select the correct drug concentration?

Selecting the correct concentration (300 mcg/mL for vials vs. 600 mcg/mL for prefilled syringes) is critical for calculating the correct volume to administer. An error here could lead to a significant dosing error.

When should filgrastim be administered relative to chemotherapy?

Filgrastim should not be given within the 24-hour period before or after the administration of cytotoxic chemotherapy, as this may increase the sensitivity of rapidly dividing myeloid cells to the chemotherapy.

Is the calculated dose suitable for pediatric patients?

The dosing for filgrastim in pediatric patients is generally the same weight-based mcg/kg dose as in adults for most indications. However, all pediatric dosing must be confirmed and supervised by a clinician specializing in pediatric hematology/oncology.

References

• Neupogen® (filgrastim) Prescribing Information. U.S. Food and Drug Administration. Amgen Inc.
• Neupogen® (filgrastim) HCP Site. Amgen Inc.
• Aapro, M. S., Bohlius, J., Cameron, D. A., et al. (2011). 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. European journal of cancer, 47(1), 8-32.
• National Comprehensive Cancer Network® (NCCN®). NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors. (Requires free registration to view).